Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SI-BONE, Inc. Director's Dealing 2021

Nov 17, 2021

32647_dirs_2021-11-17_312dc036-6298-4505-9136-1bf78ff1238c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SI-BONE, Inc. (SIBN)
CIK: 0001459839
Period of Report: 2021-11-16

Reporting Person: FRANCIS LAURA (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-11-16 Common Stock S 1020.00 $21.4697 Disposed 215943.00 Direct
2021-11-16 Common Stock S 621.00 $21.4697 Disposed 215322.00 Direct
2021-11-16 Common Stock S 1530.00 $21.4697 Disposed 213792.00 Direct
2021-11-16 Common Stock S 1678.00 $21.4697 Disposed 212114.00 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-10-25 Stock Options (Right to buy) $22.00 G 20328.00 Disposed 2029-01-15 Common Stock (20238.00) Direct

Footnotes

F1: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in
connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2: Includes 119,710 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents
a contingent right to receive one share of the Issuer's common stock.

F3: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date.

F4: The reported transaction involves the Reporting Person's transfer of options to trusts for the benefit of Reporting Person's children.